oregovomab: Clinical Trials

12 trials of oregovomab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 3 active not recruiting, 3 unknown, 2 completed. 12 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Terminated 4, Active not recruiting 3, Unknown 3, Completed 2
Phase 14Terminated 2, Active not recruiting 1, Unknown 1

Follow oregovomab: new trials by email Literature Review of oregovomab trials Research Report on oregovomab

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Oregovomab, Paclitaxel, Carboplatin - Ovarian Neoplasm Epithelial, Ovarian Cancer
Phase 2Active not recruitingCanariaBio Inc.882023-02-072026-10-23
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Oregovomab, Niraparib - Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary
Phase 2Active not recruitingCanariaBio Inc.102022-07-252026-04-03
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III
Phase 1 / Phase 2Active not recruitingCanariaBio Inc.542021-03-172026-04-06
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Oregovomab, Nivolumab, Chemotherapy - Epithelial Ovarian Cancer
Phase 1 / Phase 2UnknownNational Cancer Centre, Singapore312020-10-072021-12-01
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Nivolumab, Oregovomab - Epithelial Ovarian Cancer
Phase 1 / Phase 2TerminatedNational Cancer Centre, Singapore132017-02-222022-06-13
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride - Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Phase 2CompletedUniversity of Nebraska112013-09-062023-10-10
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Carboplatin, Paclitaxel, oregovomab - Ovarian Neoplasms
Phase 2CompletedQuest PharmaTech Inc.972012-06-152020-09-14
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
oregovomab - Ovarian Cancer
Phase 2TerminatedUnither Pharmaceuticals402004-07-012007-12-18
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
oregovomab - Ovarian Neoplasms
Phase 1 / Phase 2TerminatedUnither Pharmaceuticals242002-03-012007-12-18
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
oregovomab - Ovarian Neoplasms
Phase 2TerminatedUnither Pharmaceuticals1022000-09-012007-12-18
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
oregovomab - Fallopian Tube Cancer, Ovarian Cancer
Phase 2UnknownAltaRex1021998-11-012013-11-06
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
oregovomab - Fallopian Tube Cancer, Ovarian Cancer
Phase 2UnknownAltaRex4001998-04-012013-11-06

Conditions studied

Ovarian Neoplasms (9)  ·  Carcinoma, Ovarian Epithelial (7)  ·  Fallopian Tube Neoplasms (4)  ·  Adenocarcinoma (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

CanariaBio Inc. (3)  ·  Unither Pharmaceuticals (3)  ·  AltaRex (2)  ·  National Cancer Centre, Singapore (2)  ·  Quest PharmaTech Inc. (1)  ·  University of Nebraska (1)

Countries

United States (7)  ·  Canada (3)  ·  Singapore (2)  ·  India (1)  ·  South Korea (1)

Top investigators

Chi Lin (1)  ·  Christopher Nicodemus, MD FACP (1)  ·  Dr Jung KH, MD (1)  ·  Jack Chan (1)  ·  Jack Chan, MD (1)  ·  Jada Srinivasa Rao, PhD (1)  ·  Jonathan S. Berek, MD (1)  ·  Michael A. Bookman, MD (1)  ·  Sunil Gupta, MD, FRCPC (1)  ·  Thomas Woo, M.Sc. (1)

Results publications

PMID 31897661, PMID 31916979

NIH funding

P30CA036727 (1)